vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily	the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks	NF?B activity	-1	-1	NF?B activity also did not differ between vitamin D and placebo groups in this subgroup (p?=?0.3;
vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily	the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks	hsCRP, TNF, MCP-1, IFN-?, any of the interleukins	-1	-1	Vitamin D and placebo groups did not differ in any inflammatory markers or NFκB activity (all p�??>�??0.05).
vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily	the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks	Serum 25(OH)D concentrations	1028	1130	Serum 25(OH)D concentrations increased with vitamin D supplementation compared to placebo (p < 0.001).
vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily	the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks	hsCRP, TNF, MCP-1, IFN-?, any of the interleukins	-1	-1	There were no differences between vitamin D and placebo groups in change in hsCRP (?0.1?±?1.4 versus ?0.4?±?2.3?mg/L, p?=?0.9), TNF (?8.0?±?109.4 versus ?2.9?±?103.9?pg/ml, p?=?0.9), MCP-1 (?234.8?±?1071.9 versus ?58.8?±?819.4?pg/ml, p?=?0.6) or IFN-? (11.1?±?85.8 versus ?1.3?±?22.7?pg/ml, p?=?0.9). Similarly, no differences between vitamin D and placebo groups were found for any of the interleukins (all p?>?0.1; Table 2).
vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily	the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks	NF?B activity	1131	1235	Vitamin D and placebo groups did not differ in any inflammatory markers or NFκB activity (all p > 0.05).
